STAT

The National Institutes Of Health is set to investigate a Gilead Sciences, Inc (NASDAQ: GILD) compound, similar to remdesivir, which could be effective against COVID-19, Stat reported Monday. What Happened: The Francis Collins-led agency concluded that the compound known as GS-441524...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 15% after Thursday's market close and the encouraging report from STAT is "good news" although anecdotal, CNBC's Guy Adami said. The report is encouraging from a human point of view as keeping people safe is...

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  What Happened Biogen and its Japanese partner Eisai Co released a final analysis of 856 patients in a Phase 2 clinical study in...